Abstract
Development of optimal SARS-CoV-2 vaccines to induce potent, long-lasting immunity and provide cross-reactive protection against emerging variants remains a high priority. Here, we report that a modified porous silicon microparticle (mPSM) adjuvant to SARS-CoV-2 receptor-binding domain (RBD) vaccine activated dendritic cells and generated more potent and durable systemic humoral and type 1 helper T (Th) cell- mediated immune responses than alum-formulated RBD following parenteral vaccination, and protected mice from SARS-CoV-2 and Beta variant challenge. Notably, mPSM facilitated the uptake of SARS-CoV-2 RBD antigens by nasal and airway epithelial cells. Parenteral and intranasal prime and boost vaccinations with mPSM-RBD elicited stronger lung resident T and B cells and IgA responses compared to parenteral vaccination alone, which led to markedly diminished viral loads and inflammation in the lung following SARS-CoV-2 Delta variant challenge. Overall, our results suggest that mPSM is effective adjuvant for SARS-CoV-2 subunit vaccine in both systemic and mucosal vaccinations.
【초록키워드】 SARS-CoV-2, Inflammation, Vaccine, immune response, vaccination, Immunity, variant, lung, nasal, delta variant, SARS-CoV-2 vaccine, Antigen, B cell, Viral load, mice, RBD, Beta, development, dendritic cell, intranasal, mucosal, Vaccinations, airway epithelial cells, humoral, SARS-CoV-2 RBD, cross-reactive, Parenteral, subunit, domain, Microparticle, IgA response, effective, Cell, activated, facilitated, long-lasting, induce, elicited, porous, prime and boost, type 1 helper, 【제목키워드】 SARS-CoV-2, Vaccine, Immunity, Protective, mucosal, subunit, Microparticle, porous,